

## HR 2115

### Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 8, 2019

**Current Status:** Received in the Senate and Read twice and referred to the Committee on Finance.

**Latest Action:** Received in the Senate and Read twice and referred to the Committee on Finance. (Oct 29, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/2115>

## Sponsor

**Name:** Rep. Spanberger, Abigail [D-VA-7]

**Party:** Democratic • **State:** VA • **Chamber:** House

## Cosponsors (5 total)

| Cosponsor                          | Party / State | Role | Date Joined  |
|------------------------------------|---------------|------|--------------|
| Rep. Arrington, Jodey C. [R-TX-19] | R · TX        |      | Apr 8, 2019  |
| Rep. Boyle, Brendan F. [D-PA-2]    | D · PA        |      | Apr 8, 2019  |
| Rep. Van Drew, Jefferson [D-NJ-2]  | D · NJ        |      | May 1, 2019  |
| Rep. Slotkin, Elissa [D-MI-8]      | D · MI        |      | Oct 28, 2019 |
| Rep. Taylor, Van [R-TX-3]          | R · TX        |      | Oct 28, 2019 |

## Committee Activity

| Committee                     | Chamber | Activity                   | Date         |
|-------------------------------|---------|----------------------------|--------------|
| Energy and Commerce Committee | House   | Hearings By (subcommittee) | May 21, 2019 |
| Finance Committee             | Senate  | Referred To                | Oct 29, 2019 |
| Ways and Means Committee      | House   | Referred to                | Apr 8, 2019  |

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

| Bill        | Relationship | Last Action  |
|-------------|--------------|--|
| 116 HR 2113 | Related bill | Dec 24, 2020: Placed on the Union Calendar, Calendar No. 571.                                |
| 116 HR 19   | Related bill | Dec 19, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. |
| 116 S 3129  | Related bill | Dec 19, 2019: Read twice and referred to the Committee on Finance.                           |
| 116 HR 2296 | Related bill | Sep 24, 2019: Placed on the Union Calendar, Calendar No. 170.                                |
| 116 HR 3408 | Related bill | Jun 24, 2019: Referred to the Subcommittee on Health.  |
| 116 HR 3415 | Related bill | Jun 24, 2019: Referred to the Subcommittee on Health.  |

## Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements.

The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.

### Actions Timeline

---

- **Oct 29, 2019:** Received in the Senate and Read twice and referred to the Committee on Finance.
- **Oct 28, 2019:** Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.
- **Oct 28, 2019:** Considered under suspension of the rules. (consideration: CR H8516-8519)
- **Oct 28, 2019:** DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.
- **Oct 28, 2019:** At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
- **Oct 28, 2019:** Considered as unfinished business. (consideration: CR H8520-8521)
- **Oct 28, 2019:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
- **Oct 28, 2019:** On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
- **Oct 28, 2019:** Motion to reconsider laid on the table Agreed to without objection.
- **Oct 28, 2019:** The title of the measure was amended. Agreed to without objection.
- **May 21, 2019:** Subcommittee Hearings Held.
- **Apr 9, 2019:** Referred to the Subcommittee on Health.
- **Apr 8, 2019:** Introduced in House
- **Apr 8, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Apr 8, 2019:** Referred to the Subcommittee on Health.